Iterum Therapeutics (ITRM) to Release Quarterly Earnings on Monday

Iterum Therapeutics (NASDAQ:ITRM) is scheduled to be issuing its quarterly earnings data before the market opens on Monday, May 13th. Analysts expect the company to announce earnings of ($0.57) per share for the quarter.

Iterum Therapeutics (NASDAQ:ITRM) last released its earnings results on Thursday, March 28th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.08. On average, analysts expect Iterum Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Iterum Therapeutics Trading Up 1.3 %

Shares of Iterum Therapeutics stock traded up $0.02 during trading on Tuesday, hitting $1.61. The stock had a trading volume of 35,594 shares, compared to its average volume of 472,256. The firm’s fifty day simple moving average is $1.54 and its 200-day simple moving average is $1.54. The stock has a market cap of $26.66 million, a PE ratio of -0.53 and a beta of 2.33. The company has a debt-to-equity ratio of 3.63, a current ratio of 1.89 and a quick ratio of 1.89. Iterum Therapeutics has a 12 month low of $0.62 and a 12 month high of $2.50.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Iterum Therapeutics in a research note on Tuesday, April 30th.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.